Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France.
Pol S, Couzigou P, Bourlière M, Abergel A, Combis JM, Larrey D, Tran A, Moussalli J, Poupon R, Berthelot P, Bréchot C. Pol S, et al. Among authors: combis jm. J Hepatol. 1999 Jul;31(1):1-7. doi: 10.1016/s0168-8278(99)80157-3. J Hepatol. 1999. PMID: 10424277 Clinical Trial.
Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon.
Zarski JP, Maynard-Muet M, Chousterman S, Baud M, Barnoud R, Abergel A, Bacq Y, Combis JM, Causse X, Tran A, Oberti F, Minello A, Bresson-Hadni S, Bailly F, Raabe JJ, Leroy V, Hamici L, Hicham T, Girardin MF. Zarski JP, et al. Among authors: combis jm. Hepatology. 1998 Mar;27(3):862-7. doi: 10.1002/hep.510270332. Hepatology. 1998. PMID: 9500719 Clinical Trial.
Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France.
Ouzan D, Larrey D, Guyader D, Remy AJ, Riachi G, Heluwaert F, Truchi R, Combis JM, Bailly F, Rosa I, Hézode C, Glorian-Petraud D, Libert O, Ramroth H, Asselah T, Thiefin G, Roulot D, Roche B, Leroy V, Dumortier J, Thabut D, Pol S; HELIOS study group. Ouzan D, et al. Among authors: combis jm. Dig Dis Sci. 2021 Mar;66(3):881-898. doi: 10.1007/s10620-020-06234-1. Epub 2020 Apr 18. Dig Dis Sci. 2021. PMID: 32303953
Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy.
Martinez SM, Foucher J, Combis JM, Métivier S, Brunetto M, Capron D, Bourlière M, Bronowicki JP, Dao T, Maynard-Muet M, Lucidarme D, Merrouche W, Forns X, de Lédinghen V. Martinez SM, et al. Among authors: combis jm. PLoS One. 2012;7(10):e47715. doi: 10.1371/journal.pone.0047715. Epub 2012 Oct 17. PLoS One. 2012. PMID: 23082200 Free PMC article. Clinical Trial.
Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy.
Nicot F, Alric L, Barange K, Métivier S, Dramard JM, Combis JM, Castan B, Meurisse JJ, Payen JL, Garipuy D, Desmorat H, Peron JM, Thebault S, Morin T, Renou C, Barel P, Guerin B, Imbert Y, Sire S, Sauné K, Chatelut E, Izopet J. Nicot F, et al. Among authors: combis jm. J Med Virol. 2011 Mar;83(3):437-44. doi: 10.1002/jmv.21976. J Med Virol. 2011. PMID: 21264864 Clinical Trial.
Safety and efficacy of combination therapy with peginterferon alfa-2a (40kD) and ribavirin in the outpatient setting: prospective analysis of 197 patients with chronic hepatitis C viral infection.
Fontanges T, Beorchia S, Douvin C, Delassalle P, Combis JM, Hanslik B, Jacques JP, Filoche B, Desmorat H, Chandelier C, Ouzan D. Fontanges T, et al. Among authors: combis jm. Gastroenterol Clin Biol. 2007 Jun-Jul;31(6-7):566-72. doi: 10.1016/s0399-8320(07)89432-2. Gastroenterol Clin Biol. 2007. PMID: 17646782 Free article. Clinical Trial.
26 results